Bedinvetmab v. Meloxicam: A Randomized, Open-Label, Multi-Centre, Parallel-Group Trial

Course overview

Join us for an in-depth exploration of the latest advancements in osteoarthritis (OA) management for dogs, with a focus on comparing two critical treatments: Bedinvetmab and Meloxicam. Led by Dr. John Innes, BVSc, PhD, FRCVS, this session will examine the efficacy, safety, and impact of these treatments in improving the quality of life for dogs suffering from OA. The presentation will be based on findings from multi-center clinical trials, revealing how nerve growth factor (NGF) targeting with Bedinvetmab compares to the established NSAID therapy using Meloxicam. Attendees will gain insights into clinical outcomes, adverse events, and key metrics used to assess treatment success in managing pain and inflammation.